Early results from CASCARA: A phase 2 study of cabazitaxel/carboplatin plus abiraterone in high-volume metastatic castrate-sensitive prostate cancer (mCSPC).

Share on Pinterest UCLA researchers recently found that PSA levels after prostate cancer treatment may not be the best indicator of survival. andresr/Getty Images A new study from UCLA researchers ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor Prostate Specific Antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Treatment outcomes for patients with Ga68-PSMA-PET prostate cancer (PC) with or without conventional imaging correlates. Validation of a digital pathology-based multimodal artificial intelligence ...

Making dietary changes, such as eating more tomatoes, cruciferous vegetables, and berries, may help lower PSA levels and reduce the risk of prostate cancer. Increasing physical activity to at least ...

Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

After surgical removal of the prostate to treat prostate cancer, clinicians monitor prostate specific antigen (PSA) levels. Persistently elevated PSA levels indicate residual cancer and are linked to ...

Men with metastatic hormone-sensitive prostate cancer treated with Nubeqa, androgen-deprivation therapy and docetaxel had reductions in PSA levels that were associated with improved overall survival ...